TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03662360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils
Description: Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
Study: NCT02009696

Intervention type: DEVICE
Intervention: Patients with a ProMRI Pacemaker System
Description: Bradycardia Slow Heart Beat

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: MRI scan of heart/chest or thoracic spine.
Study: NCT03936140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
Study: NCT01364974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01642069

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03479190

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided injection of Platelet rich plasma
Description: Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guided injection of Normal Saline
Description: ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
Study: NCT01354275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle
Description: 150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle
Description: 150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GnRH Antagonist
Description: GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
Study: NCT02069769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication with oncology team
Description: Oncology team will contact patients and families via telephone at specific intervals
Study: NCT01569035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: 3 mg warfarin oral tablet for 2 to 3 weeks
Study: NCT00798356

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga training
Description: Yoga training for 12 weeks
Study: NCT00025584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03584776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
Study: NCT03736564

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE PET/CT
Description: Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
Study: NCT00630214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral calcium plus vitamin D
Description: calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral calcium alone
Description: calcium carbonate (3 g/day, 1 g every 8 h)
Study: NCT03176589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: positive expiratory pressure (PEP)
Description: Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo comparator, Deep inspiration and expression in a placebo tube without resistance
Description: Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing maneuvers
Description: deep breathing maneuvers 3 times 10 breahs without any device at expiration
Study: NCT03547284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugarless gum
Description: 81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
Study: NCT01267981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard diet
Description: After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet + 500 ml of polyethyleneglycol
Description: Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol
Description: apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
Study: NCT02452866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYM-1219
Description: Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
Study: NCT02853266

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Archived serum samples are analysed for measurement of biomarker NCRA

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Archived serum samples are analysed for measurement of biomarker NCRA
Study: NCT01412814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy Biomechanical System
Description: The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Program
Description: Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
Study: NCT03380780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
Study: NCT03864601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ-56136379
Description: 14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
Study: NCT01120080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Intervention Counseling
Description: The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
Study: NCT02091596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PluroGel N
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PluroGel
Description: PluroGel Vehicle Placebo Comparator
Study: NCT01793480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study: NCT03832790

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT01645891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CDO electrochemical tissue oxygenation system
Description: The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Moist Wound Therapy
Description: Moist Wound Therapy in combination with sham or deactivated device
Study: NCT02589522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo whole-brain radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo whole-brain radiation therapy
Study: NCT04403503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate, Isobutyl
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
Study: NCT03543098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Surgery
Description: Subjects will undergo surgery within 6 weeks after injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Surgery
Description: Subjects will undergo surgery within 6 weeks after injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Surgery
Description: Subjects will undergo surgery 12 to 16 weeks after injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Surgery
Description: Subjects will undergo surgery 12 to 16 weeks after injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Rehab
Description: Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Rehab
Description: Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Rehab
Description: Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Rehab
Description: Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Rehab
Description: Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Rehab
Description: Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
Study: NCT02733185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: disodium EDTA
Description: IV Disodium Ethylene diamine tetra acetic acid in 500 cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: disodium EDTA
Description: IV Disodium Ethylene diamine tetra acetic acid in 500 cc

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Multi Vitamins/Minerals (OMVM)
Description: 6 tablets of Multi-vitamin/Multimineral daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Multi Vitamins/Minerals (OMVM)
Description: 6 tablets of Multi-vitamin/Multimineral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo disodium EDTA
Description: IV Placebo comparator- 500 normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo disodium EDTA
Description: IV Placebo comparator- 500 normal saline

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Multi Vitamins/Minerals (OMVM)
Description: 6 tablets of a placebo Multi-vitamin/Multimineral daily
Study: NCT04712019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Incision Negative Pressure Therapy (ciNPT)
Description: Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric at 125mmHg of continuous negative pressure on a closed surgical incision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Silver-containing Dressing
Description: A standard silver-containing dressing applied to a closed surgical incision
Study: NCT03824132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvisational comedy classes
Description: 6 consecutive improvisational comedy classes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
Study: NCT01943851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
Study: NCT06558747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
Study: NCT03863171

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial spin labeling (ASL) magnetic resonance imaging
Description: Arterial spin labeling (ASL) magnetic resonance imaging test

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial spin labeling (ASL) magnetic resonance imaging
Description: Arterial spin labeling (ASL) magnetic resonance imaging test

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus fluorescein angiography
Description: Fundus fluorescein angiography test

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus fluorescein angiography
Description: Fundus fluorescein angiography test
Study: NCT03605862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for five days
Study: NCT04448067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Lentil Intake
Description: Dietary intake of moderate or high dose of lentils at midday meals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Lentil Intake
Description: Dietary intake of moderate or high dose of lentils at midday meals

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Dietary Lentil CONTROL
Description: Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
Study: NCT02584998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mailed-FIT
Description: The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening invitation-reminder
Description: These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
Study: NCT02965196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Dexamethasone Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Normal Saline (NaCl 0.9%)
Study: NCT03892577

Intervention type: DRUG
Intervention: Precision oncology including targeted therapy and immunotherapy
Description: Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.